Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

NOVARTIS AG (NVS)

As of 2026-11-20 · 11/15 boxes filled from SEC filings and market data

Report price $151.22 (close 2026-11-19); latest close $150.47 (2026-11-20), -0.5% since the report; figures re-marked at the latest close

Conclusion: WATCH

Conviction low · base case +90% · downside -32% · upside +101%

At $151.22 Novartis is priced for modest durability, not a re-rating: 20.6x FY2025 net income and 17.3x FY2025 EBIT, a 5.8% EBIT yield against a 5.5% WACC, with ROIC of 23.1% and a 6.1% FCF yield. The multiple is cheap because the largest patent expiry in company history is still eroding US sales and two Phase III misses removed near-term pipeline offsets. That discount is defensible, but the gap to peers is peer-set rather than Novartis-specific. The base case is $285.56, +88.8%, on the P/E at 38.9x, the peer median P/E across nine peers spanning 12.9x to 133.5x. The upside case is $302.44, +100.0%, on the base case's multiple on +10% earnings. The downside case is $102.83, -32.0%, on -20.0% earnings at a compressed P/E of 17.51x. Both the base and the upside sit far above today's price, yet neither is a company-specific anchor and the downside is not protected, so the call is WATCH at low conviction.

Key numbers

  • Share price: $150.47
  • Market cap: $287.12B
  • Latest financial period: TTM to Dec 31, 2025
  • P/E (FY Dec 2025): 20.5x
  • FCF yield: 6.1%
  • Price / book: 6.23x
  • EV / FCF (FY Dec 2025): 17.3x
  • ROIC (FY Dec 2025): 23.1%
  • WACC: 5.5%
  • Economic profit spread: +17.5 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Novartis is now a pure innovative-medicines company: FY2025 net sales from continuing operations were USD 54.5B, split across oncology USD 16.8B, immunology USD 10.3B, cardiovascular/renal/metabolic USD 9.0B, neuroscience USD 6.0B and established brands USD 12.5B. The oldest report here, FY2020, shows a different two-division company—Innovative Medicines USD 39.0B plus Sandoz USD 9.6B—and the Sandoz spin-off completed October 3, 2023 removed Sandoz, so FY2020 and FY2025 sales are not like-for-like. FY2025 growth was concentrated in Kisqali, Kesimpta, Pluvicto and Scemblix, offset by generic erosion in Entresto, Promacta/Revolade and Tasigna; the FY2025 operating margin was 32.4% and core operating margin 40.1%, with free cash flow of USD 17.6B.

  2. ✓ 2. Competitive advantage

    The sources support a large, cash-generative R&D organization but not an explicit durable moat: FY2025 gross profit was $42.98B and operating cash flow $19.14B, with operating income positive every year FY2020-FY2025. The 20-F bases protection on intellectual property and regulatory exclusivities while describing intense competition from major pharma, regional/national firms, generics/biosimilars and new tech entrants, and it says generic/biosimilar entry may follow expiry or successful IP challenges. R&D is long (10-15 years) and risky, so the advantage is not presented as permanent.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 net sales rose 4% USD and 4% cc to USD 14.522bn, with volume +14 pp partly offset by generic competition -9 pp; US +7%, rest of world +3%. Operating income fell 59% to USD 1.843bn and margin to 12.7% on a USD 1.9bn del-desiran IPR&D impairment and higher other expense, while core operating income rose 11% to USD 6.036bn and core margin rose to 41.6%. Cash was lower: Q3 operating cash flow USD 5.503bn (-16%) and FCF USD 5.111bn (-18%); 9M net debt rose to USD 37.4bn and the company used USD 4.8bn net for treasury shares plus a USD 9.1bn annual dividend.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ○ 9. Insider trading interpretation
  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans